相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cirrhotic stiffness affects the migration of hepatocellular carcinoma cells and induces sorafenib resistance through YAP
Jian Gao et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Pin1 inhibition reverses the acquired resistance of human hepatocellular carcinoma cells to Regorafenib via the Gli1/Snail/E-cadherin pathway
Jichuang Wang et al.
CANCER LETTERS (2019)
Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma
Michael Teufel et al.
GASTROENTEROLOGY (2019)
Functional significance of Hippo/YAP signaling for drug resistance in colorectal cancer
Ruolan Song et al.
MOLECULAR CARCINOGENESIS (2018)
Inhibition of YAP reverses primary resistance to EGFR inhibitors in colorectal cancer cells
Bi-Sheng Liu et al.
ONCOLOGY REPORTS (2018)
Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway
Zhiqiang Li et al.
CANCER CELL (2018)
YAP/TAZ Signaling as a Molecular Link between Fibrosis and Cancer
Satoshi Noguchi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Molecular profiling of nonalcoholic fatty liver disease-associated hepatocellular carcinoma using SB transposon mutagenesis
Takahiro Kodama et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Emerging therapies in advanced hepatocellular carcinoma
Sowmini Medavaram et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2018)
Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies
Min Hwan Kim et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2017)
FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation
J. Tong et al.
ONCOGENE (2017)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer
Michiko Kodama et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Inhibition of YAP function overcomes BRAF inhibitor resistance in melanoma cancer stem cells
Matthew L. Fisher et al.
ONCOTARGET (2017)
A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220
Panpan Hou et al.
CANCER RESEARCH (2017)
Involvement of Notch-1 in Resistance to Regorafenib in Colon Cancer Cells
Giovanna Mirone et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2016)
Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
John G. Doench et al.
NATURE BIOTECHNOLOGY (2016)
YAP induces cisplatin resistance through activation of autophagy in human ovarian carcinoma cells
Lan Xiao et al.
ONCOTARGETS AND THERAPY (2016)
Nuclear translocation and activation of YAP by hypoxia contributes to the chemoresistance of SN38 in hepatocellular carcinoma cells
Xiao-Yang Dai et al.
ONCOTARGET (2016)
A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia
Konstantinos Tzelepis et al.
CELL REPORTS (2016)
A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis
Toshiro Moroishi et al.
GENES & DEVELOPMENT (2015)
The Hippo pathway transcriptional co-activator, YAP, confers resistance to cisplatin in human oral squamous cell carcinoma
Kyohei Yoshikawa et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
YAP and the drug resistance highway
Alona Keren-Paz et al.
NATURE GENETICS (2015)
The Hippo signaling pathway in liver regeneration and tumorigenesis
Lixin Hong et al.
ACTA BIOCHIMICA ET BIOPHYSICA SINICA (2015)
The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment
Randy Johnson et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
SIRT1 regulates YAP2-mediated cell proliferation and chemoresistance in hepatocellular carcinoma
B. Mao et al.
ONCOGENE (2014)
Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells
Ophir Shalem et al.
SCIENCE (2014)
Overexpression of Yes-associated protein confers doxorubicin resistance in hepatocellullar carcinoma
Xinying Huo et al.
ONCOLOGY REPORTS (2013)
Regulation of the Hippo-YAP pathway by protease-activated receptors (PARs)
Jung-Soon Mo et al.
GENES & DEVELOPMENT (2012)
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina et al.
NATURE (2012)
Treatment of Hepatocellular Carcinoma: A Systematic Review
Shibo Lin et al.
LIVER CANCER (2012)
Increases in p53 expression induce CTGF synthesis by mouse and human hepatocytes and result in liver fibrosis in mice
Takahiro Kodama et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression
Hai Song et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Mst1 and Mst2 Maintain Hepatocyte Quiescence and Suppress Hepatocellular Carcinoma Development through Inactivation of the Yap1 Oncogene
Dawang Zhou et al.
CANCER CELL (2009)
Elucidation of a universal size-control mechanism in Drosophila and mammals
Jixin Dong et al.
CELL (2007)
分享论文
